PMC6370032_01
MRI concluded benign prostatic hyperplasia. MRI = magnetic resonance imaging.
medi-98-e14155-g001.jpg
PMC6370032_01_medi-98-e14155-g001.jpg
F1
The patient underwent further evaluation, including bone scintigraphy, and magnetic resonance imaging (MRI) (Fig. 1), which revealed no metastasis.
Transrectal prostatic biopsy and negative pathological staining. A. Transrectal prostatic biopsy (HE x 100) B. Transrectal prostatic biopsy (HE x 400) C. Diffusely negative staining for PSA.D. Diffusely negative staining for P504 s. MRI = magnetic resonance imaging.
medi-98-e14155-g002.jpg
PMC6370032_01_medi-98-e14155-g002.jpg
F2
Histopathological examination showed high-grade prostatic urothelial carcinoma [Immunohistochemistry: CK5/6(-), CK7(+), CgA(-), GATA-3(+,55%), P40(+), P504s(-), P63(+), PSA(-), Syn(-), uroplakim III(+), and CD56(-)] (Figs. 2 and 3).
Positive pathological staining. A. Diffusely positive staining for GATA-3. B. Diffusely positive staining for Uroplakim III. C. Diffusely positive staining for CK7. D. Diffusely positive staining for P63.
medi-98-e14155-g003.jpg
PMC6370032_01_medi-98-e14155-g003.jpg
F3
Histopathological examination showed high-grade prostatic urothelial carcinoma [Immunohistochemistry: CK5/6(-), CK7(+), CgA(-), GATA-3(+,55%), P40(+), P504s(-), P63(+), PSA(-), Syn(-), uroplakim III(+), and CD56(-)] (Figs. 2 and 3).
Postoperative pathology and imaging data A. Postoperative prostate tissue (HE x 100) B. Postoperative prostate tissue (HE x 400). C. Postoperative gross specimen, Left lymph node (red arrow), right lymph node (blue arrow) and Right ureteral stump (green arrow) D. Postoperative CT image. CT = computed tomography.
medi-98-e14155-g004.jpg
PMC6370032_01_medi-98-e14155-g004.jpg
F4
The results of the histopathological examination showed primary urothelial carcinoma of the prostate (Fig. 4A and B). One and 3 lymph node metastases were found around the left and right iliac vessels, respectively (Fig. 4C). Computed tomography (CT) found no tumor recurrence during the 6-month follow-up period (Fig. 4D).